Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies9
  • 7D-0.7%
  • 3M-0.5%
  • 1Y36.7%
  • YTD3.7%

Last week, the Pharma industry hasn't moved much but Sandoz Group is up 3.3% in that time. The past year has been better, since the industry has gained 37% in that time. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026CHF 556.0bCHF 121.2bCHF 25.1b39x22.1x4.6x
Thu, 12 Mar 2026CHF 563.4bCHF 120.9bCHF 25.1b37.2x22.5x4.7x
Sat, 07 Feb 2026CHF 581.7bCHF 119.8bCHF 24.4b37.1x23.9x4.9x
Mon, 05 Jan 2026CHF 560.6bCHF 120.9bCHF 21.5b35x26.1x4.6x
Wed, 03 Dec 2025CHF 540.2bCHF 121.7bCHF 21.6b34.4x25x4.4x
Fri, 31 Oct 2025CHF 477.8bCHF 121.5bCHF 21.6b32.6x22.1x3.9x
Sun, 28 Sep 2025CHF 465.5bCHF 120.2bCHF 20.9b30.6x22.2x3.9x
Tue, 26 Aug 2025CHF 478.4bCHF 120.9bCHF 21.1b30.8x22.7x4x
Thu, 24 Jul 2025CHF 445.1bCHF 118.5bCHF 19.5b25.1x22.8x3.8x
Sat, 21 Jun 2025CHF 444.4bCHF 118.7bCHF 19.2b24.9x23.2x3.7x
Mon, 19 May 2025CHF 432.1bCHF 120.1bCHF 19.5b25x22.2x3.6x
Wed, 16 Apr 2025CHF 412.8bCHF 117.7bCHF 18.5b24.5x22.3x3.5x
Fri, 14 Mar 2025CHF 475.6bCHF 121.7bCHF 19.2b29.1x24.8x3.9x
Sun, 09 Feb 2025CHF 474.0bCHF 123.1bCHF 19.2b22.7x24.6x3.9x
Tue, 07 Jan 2025CHF 430.3bCHF 119.3bCHF 21.4b18x20.1x3.6x
Thu, 05 Dec 2024CHF 426.3bCHF 118.0bCHF 21.1b18.2x20.2x3.6x
Sat, 02 Nov 2024CHF 452.2bCHF 117.1bCHF 21.0b19.6x21.5x3.9x
Mon, 30 Sep 2024CHF 457.4bCHF 114.3bCHF 19.2b21.9x23.8x4x
Wed, 28 Aug 2024CHF 471.1bCHF 114.4bCHF 19.2b22.6x24.5x4.1x
Fri, 26 Jul 2024CHF 456.1bCHF 116.3bCHF 20.5b32.7x22.3x3.9x
Sun, 23 Jun 2024CHF 432.4bCHF 116.2bCHF 19.7b33.9x21.9x3.7x
Tue, 21 May 2024CHF 417.8bCHF 113.3bCHF 19.9b40.3x21x3.7x
Thu, 18 Apr 2024CHF 394.5bCHF 112.4bCHF 19.5b36.6x20.3x3.5x
Sat, 16 Mar 2024CHF 376.8bCHF 110.9bCHF 19.2b37.3x19.6x3.4x
Mon, 12 Feb 2024CHF 377.4bCHF 110.0bCHF 19.6b24.1x19.2x3.4x
Wed, 10 Jan 2024CHF 415.4bCHF 119.4bCHF 18.6b27x22.3x3.5x
Fri, 08 Dec 2023CHF 396.8bCHF 120.9bCHF 18.9b24.3x21x3.3x
Sun, 05 Nov 2023CHF 384.3bCHF 122.4bCHF 19.1b23.4x20.2x3.1x
Tue, 03 Oct 2023CHF 407.6bCHF 113.8bCHF 18.2b44.6x22.4x3.6x
Thu, 31 Aug 2023CHF 408.5bCHF 111.6bCHF 17.9b47.6x22.8x3.7x
Sat, 29 Jul 2023CHF 415.6bCHF 114.4bCHF 19.2b48x21.6x3.6x
Mon, 26 Jun 2023CHF 425.0bCHF 115.2bCHF 18.9b37.3x22.5x3.7x
Wed, 24 May 2023CHF 434.0bCHF 115.4bCHF 18.9b39.5x22.9x3.8x
Fri, 21 Apr 2023CHF 436.2bCHF 114.7bCHF 18.8b42.5x23.2x3.8x
Price to Earnings Ratio

23.2x


Total Market Cap: CHF 436.2bTotal Earnings: CHF 18.8bTotal Revenue: CHF 114.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.8x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.56%
Healthcare-0.28%
Pharma-0.72%
Pharma-0.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SDZ Sandoz GroupCHF 66.103.3%
+CHF 908.7m		102.0%PE39.9x
GALD Galderma GroupCHF 158.901.5%
+CHF 563.0m		102.2%PE77.6x
COPN Cosmo PharmaceuticalsCHF 91.805.6%
+CHF 79.3m		89.9%PS15.5x
NWRN Newron PharmaceuticalsCHF 16.367.6%
+CHF 24.1m		152.1%PS19.3x
CURN Curatis HoldingCHF 22.700.9%
+CHF 1.0m		114.2%PS10.8x

Latest News

BIOV
CHF 27.00
BioVersys
7D
-8.8%
1Y
-19.6%
ROP
CHF 317.20
Roche Holding
7D
-0.3%
1Y
26.0%
NOVN
CHF 120.62
Novartis
7D
-2.1%
1Y
35.9%

NOVN: Dermatology And Immunology Pipeline Plus Dividend Will Shape Balanced Outlook

Analysts have slightly reduced their Novartis price target to CHF121.41 from CHF121.50. This change reflects updated assumptions that combine a somewhat lower revenue growth outlook with a modestly higher profit margin and a small adjustment to the future P/E multiple.
GALD
CHF 158.90
Galderma Group
7D
1.5%
1Y
102.2%
COPN
CHF 91.80
Cosmo Pharmaceuticals
7D
5.6%
1Y
89.9%

COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential

Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).
NWRN
CHF 16.36
Newron Pharmaceuticals
7D
7.6%
1Y
152.1%

Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects

Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals is a biopharmaceutical company focused on developing evenamide as an add-on therapy for schizophrenia and related central nervous system disorders. What are the underlying business or industry changes driving this perspective?
SDZ
CHF 66.10
Sandoz Group
7D
3.3%
1Y
102.0%
ADXN
CHF 0.046
Addex Therapeutics
7D
7.5%
1Y
-12.2%
DESN
CHF 341.00
Dottikon ES Holding
7D
-0.3%
1Y
89.9%
CURN
CHF 22.70
Curatis Holding
7D
0.9%
1Y
114.2%